Last reviewed 2026-04-20 · How we verify

Degarelix acetate, Leuprolide acetate

At a glance

Approved indications

No approved indications tracked.

Common side effects

• Fatigue
• Hot flashes
• White blood cell decreased
• Neutrophil count decreased
• Alopecia
• Anemia
• Dysgeusia
• Rash maculo-papular
• Nausea
• Insomnia
• Urinary frequency
• Diarrhea

Key clinical trials

• Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular Tracers (PHASE2, PHASE3)
• Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response (PHASE2)
• Assessing Efficacy of Neoadjuvant ADT in Localized High-Risk Prostate Cancer Patients Utilizing 18F-Flotufolastat PSMA PET/CT (PHASE2)
• Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging (PHASE3)
• Neo-DAB: Darolutamide and Abemaciclib in Prostate Cancer (PHASE1)
• Finite Androgen Ablation With or Without Abiraterone Acetate and Prednisone in Treating Patients With Recurrent Prostate Cancer (PHASE2)
• Safety and Efficacy Evaluation of LC-K76 in Patients With Metastatic Hormone-Sensitive Prostate Cancer (EARLY_PHASE1)
• A Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men With Metastatic Prostate Cancer That Has Become Resistant To Testosterone-Deprivation Therapy (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Degarelix acetate, Leuprolide acetate CI brief — competitive landscape report
• Degarelix acetate, Leuprolide acetate updates RSS · CI watch RSS
• Urology of Virginia portfolio CI